HomeCompareMNKKQ vs DGRO

MNKKQ vs DGRO: Dividend Comparison 2026

MNKKQ yields 10000.00% · DGRO yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MNKKQ wins by $55137509079256512.00M in total portfolio value
10 years
MNKKQ
MNKKQ
● Live price
10000.00%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$55137509079256512.00M
Annual income
$54,073,795,673,722,890,000,000.00
Full MNKKQ calculator →
DGRO
iShares Core Dividend Growth ETF
● Live price
2.13%
Share price
$68.98
Annual div
$1.47
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.6K
Annual income
$239.96
Full DGRO calculator →

Portfolio growth — MNKKQ vs DGRO

📍 MNKKQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMNKKQDGRO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MNKKQ + DGRO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MNKKQ pays
DGRO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MNKKQ
Annual income on $10K today (after 15% tax)
$850,000.00/yr
After 10yr DRIP, annual income (after tax)
$45,962,726,322,664,450,000,000.00/yr
DGRO
Annual income on $10K today (after 15% tax)
$181.24/yr
After 10yr DRIP, annual income (after tax)
$203.97/yr
At 15% tax rate, MNKKQ beats the other by $45,962,726,322,664,450,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MNKKQ + DGRO for your $10,000?

MNKKQ: 50%DGRO: 50%
100% DGRO50/50100% MNKKQ
Portfolio after 10yr
$27568754539628256.00M
Annual income
$27,036,897,836,861,443,000,000.00/yr
Blended yield
98.07%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MNKKQ buys
0
DGRO buys
0
No recent congressional trades found for MNKKQ or DGRO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMNKKQDGRO
Forward yield10000.00%2.13%
Annual dividend / share$2.00$1.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$55137509079256512.00M$31.6K
Annual income after 10y$54,073,795,673,722,890,000,000.00$239.96
Total dividends collected$55066727460582336.00M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: MNKKQ vs DGRO ($10,000, DRIP)

YearMNKKQ PortfolioMNKKQ Income/yrDGRO PortfolioDGRO Income/yrGap
1← crossover$1,010,700$1,000,000.00$11,293$213.22+$999.4KMNKKQ
2$95,539,393$94,457,943.93$12,730$217.32+$95.53MMNKKQ
3$8,447,007,736$8,344,780,585.66$14,326$221.10+$8446.99MMNKKQ
4$698,565,746,383$689,527,448,105.17$16,098$224.56+$698565.73MMNKKQ
5$54,040,711,670,213$53,293,246,321,583.74$18,064$227.74+$54040711.65MMNKKQ
6$3,910,851,616,519,516$3,853,028,055,032,387.00$20,246$230.65+$3910851616.50MMNKKQ
7$264,781,167,546,477,440$260,596,556,316,801,570.00$22,666$233.30+$264781167546.45MMNKKQ
8$16,772,556,223,821,672,000$16,489,240,374,546,942,000.00$25,349$235.73+$16772556223821.65MMNKKQ
9$994,124,678,068,810,000,000$976,178,042,909,320,800,000.00$28,325$237.94+$994124678068810.00MMNKKQ
10$55,137,509,079,256,515,000,000$54,073,795,673,722,890,000,000.00$31,624$239.96+$55137509079256512.00MMNKKQ

MNKKQ vs DGRO: Complete Analysis 2026

MNKKQStock

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full MNKKQ Calculator →

DGROETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →
📬

Get this MNKKQ vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MNKKQ vs SCHDMNKKQ vs JEPIMNKKQ vs OMNKKQ vs KOMNKKQ vs MAINMNKKQ vs VIGMNKKQ vs NOBLMNKKQ vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.